Published in:
Open Access 01-12-2018 | Correction
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
Published in: Journal of Hematology & Oncology | Issue 1/2018
Login to get accessExcerpt
The original article [1] contains two errors in Table 2:
1)
The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.
2)
The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.
Table 2
Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib
|
Clinical outcomes
|
With adverse events (n = 150)
|
Without adverse events (n = 119)
|
Unadjusted analysis
|
Multi-adjusted analysisa
|
||
|---|---|---|---|---|---|---|
|
HR/ORb (95% CI)
|
P valuec
|
HR/OR (95% CI)
|
P valued
|
|||
|
Median overall survival (IQR), days
|
169 (96–255)
|
103 (58–201)
|
0.67 (0.51,0.88)
|
0.0039
|
0.64 (0.48,0.84)
|
0.001
|
|
Median progression-free survival (IQR), days
|
86.5 (57–150)
|
62 (41–121)
|
0.75 (0.58,0.98)
|
0.0309
|
0.69 (0.53,0.91)
|
0.007
|
|
Disease control rate, n (%)
|
82 (54.67)
|
39 (32.77)
|
2.47 (1.46,4.21)
|
< 0.001
|
2.67 (1.59,4.47)
|
< 0.001
|
|
Objective response rate, n (%)
|
11 (7.33)
|
6 (5.04)
|
1.49 (0.49.5.06)
|
0.443
|
1.42 (0.50,4.01)
|
0.505
|